Drug interactions between Eylea and Lucentis
|Eylea (aflibercept ophthalmic)|
|Lucentis (ranibizumab ophthalmic)|
Interactions between your drugs
There were no interactions found in our database between Eylea and Lucentis - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.
A total of 0 drugs are known to interact with Eylea.
- Eylea is in the drug class anti-angiogenic ophthalmic agents.
- Eylea is used to treat the following conditions:
- Lucentis is a member of the drug class anti-angiogenic ophthalmic agents.
- Lucentis is used to treat the following conditions:
Drug and food interactions
No results found in our database - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
Ocular VEGF antagonists
The recommended maximum number of medicines in the 'ocular VEGF antagonists' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'ocular VEGF antagonists' category:
- aflibercept ophthalmic
- ranibizumab ophthalmic
Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.